

NOTICE REQUIRED UNDER ASX LISTING RULE 3.13.1

INOVIQ Limited (ASX:IIQ) (**INOVIQ** or the **Company**) advises that the Annual General Meeting (AGM) is scheduled for 27 November 2025. The closing date for the receipt of nominations from persons wishing to be considered for election as a director of the Company is 9 October 2025. Any nominations must be received in writing no later than 5.00pm (AEDT) on 9 October 2025 at the Company's registered office or via email to medwards@inoviq.com.

Shareholders will be advised of further details regarding the AGM in a separate Notice of Meeting which will be provided in due course.

Authorised for release by the Company Secretary, Mark Edwards.

- ENDS -

FURTHER INFORMATION

Dr Leearne Hinch
Chief Executive Officer
E lhinch@inoviq.com
M +61 400 414 416

David Williams
Chairman
E dwilliams@kidder.com.au
M +61 414 383 593

ABOUT INOVIQ LTD

INOVIQ Ltd (ASX: IIQ) is a leader in exosome technology advancing next-generation diagnostics and therapeutics that transform cancer care. Our product portfolio includes commercial-stage exosome isolation products, clinical-stage diagnostics for ovarian and breast cancers, and a cutting-edge preclinical CAR-exosome therapeutic program for solid tumours. INOVIQ is shaping the future of cancer detection and treatment to improve patient outcomes. For more information on INOVIQ, visit www.inoviq.com.